Lexicon Pharmaceuticals, Inc.

NASDAQ•LXRX

CEO: Mr. Brian T. Crum

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2000-04-07

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Contact Information

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, 77381, United States

281-863-3000

www.lexpharma.com

Market Cap

$682.13M

P/E (TTM)

-11.6

17.5

Dividend Yield

52W High

$1.83

52W Low

$0.32

52W Range

85%

Rank58Top 85.6%

2.3

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$5.49M+0.00%

4-Quarter Trend

EPS

-$0.04+0.00%

4-Quarter Trend

FCF

-$17.23M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Jump Total revenues reached $49.8 M, driven by $45.0 M licensing revenue from Novo Nordisk deal in 2025.

Net Loss Significantly Reduced 2025 net loss narrowed to $50.3 M, a major improvement from $200.4 M loss reported in the prior year.

Operating Expenses Cut SG&A expenses dropped 74% to $37.3 M following late 2024 restructuring and reduced marketing efforts.

Pipeline Advancement Continues Advancing sotagliflozin HCM Phase 3 trial; preparing NDA resubmission for ZYNQUISTA in Type 1 Diabetes indication.

Risk Factors

Pilavapadin Phase 3 Capital Needs Requires substantial additional capital for pilavapadin DPNP Phase 3 development; current resources fund only 12 months.

ZYNQUISTA Regulatory Hurdles ZYNQUISTA Type 1 Diabetes NDA review remains ongoing following multiple FDA complete response letters received.

Concentrated Stock Ownership Invus affiliates own 50.6% post-conversion, exerting substantial control over corporate governance and decisions.

Reliance on Third-Party Manufacturing Manufacturing relies on CMOs; supply chain disruptions or non-compliance pose material risks to product availability.

Outlook

Advance Key Drug Candidates Continue funding R&D for sotagliflozin (HCM) and pilavapadin (neuropathic pain) development through collaborations.

Potential NDA Resubmission Planned Preparing ZYNQUISTA NDA resubmission for Type 1 Diabetes pending STENO1 study data completion and safety review.

LX9851 Development Transfer Novo Nordisk is responsible for LX9851 clinical development following IND-enabling studies completion by year-end 2025.

Maintain Cash Runway Current cash balances plus expected collaboration revenues sufficient to fund currently planned operations for next 12 months.

Peer Comparison

Revenue (TTM)

RGNX

$170.44M

+104.5%

ADCT

$81.36M

+14.9%

LXRX

$49.80M

+60.2%

Gross Margin (Latest Quarter)

OCGN

100.0%

+0.0pp

BCYC

100.0%

+1705.8pp

GOSS

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CRVS	$1.32B	-81.2	-23.3%	1.3%
RAPT	$959.26M	-14.8	-61.8%	1.6%
OMER	$789.83M	-6.1	57.3%	103.2%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

63.3%

Strong Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

25%

Cash Flow Needs Attention

Deep Research

Next earnings:Apr 30, 2026

EPS:-$0.04

Revenue:$9.39M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data